Orforglipron vs Tirzepatide

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicOrforglipronTirzepatide
What it is

Not a peptide: a small molecule often looked up alongside peptides6

A synthetic small-molecule, nonpeptide agonist of the GLP-1 receptor, the active ingredient of Foundayo.2,6

A GIP receptor and GLP-1 receptor agonist. The Zepbound label states that it selectively binds to and activates both receptors.3

FDA status

FDA-approved

FDA-approved as Foundayo for weight reduction in adults1,2

FDA-approved. Drugs@FDA lists Foundayo with an original approval date of April 1, 2026. The label has a boxed warning about the risk of thyroid C-cell tumors.1,2

Is orforglipron FDA-approved?

FDA-approved

FDA-approved as Mounjaro and Zepbound3,4,5

FDA-approved. Drugs@FDA lists Mounjaro (first approved May 13, 2022) and Zepbound (November 8, 2023). The Zepbound label carries a boxed warning about thyroid C-cell tumors seen in rats.3,4,5

Is tirzepatide FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.7

Not among the six peptides the policy lists.7

FDA compounding safety-risk page

Not addressed in this profile’s sources.

Not addressed in this profile’s sources.

Kinds of studies cited

Large randomized human trials

  • Large randomized human trial ATTAIN-1 (NCT05869903): a 72-week randomized, double-blind, placebo-controlled trial in 3,127 adults with obesity but without diabetes, in which average weight loss was 7.5% to 11.2% depending on strength, compared with 2.1% on placebo.2,6
  • Large randomized human trial Trial 2 (NCT05872620): a 72-week randomized, double-blind, placebo-controlled trial in 1,613 adults with overweight or obesity and type 2 diabetes, described in the label.2

Large randomized human trials

  • Large randomized human trial A 72-week randomized, double-blind, placebo-controlled weight trial (NCT04184622) that enrolled 2,539 adults with obesity, or overweight with a weight-related condition, and excluded type 2 diabetes.3
  • Large randomized human trial A 72-week randomized, double-blind, placebo-controlled weight trial (NCT04657003) in 938 adults with type 2 diabetes and overweight or obesity.3
  • Controlled human trial Two 52-week randomized, double-blind, placebo-controlled sleep apnea trials (NCT05412004) that together enrolled 469 adults with obesity.3
  • Large randomized human trial SURPASS-CVOT, which compared tirzepatide with dulaglutide on major adverse cardiovascular events in people with type 2 diabetes. FDA’s August 2026 letter cites it as the basis for the new Mounjaro indication.8,9
Records collected

25 ClinicalTrials.gov records and 7 PubMed records collected

108 ClinicalTrials.gov records and 75 PubMed records collected

Area of study

Metabolic and weight2

Metabolic and weight3

Latest dated events
  1. DailyMed publishes version 10 of the Foundayo label, the version cited here.2
  2. FDA approves Foundayo, NDA 220934, according to Drugs@FDA.1
  3. The ATTAIN-1 trial of 3,127 adults with obesity is published.6
  1. FDA’s page on unapproved GLP-1 drugs is updated, as shown by its content-current date.10
  2. DailyMed publishes the Zepbound label version cited on this page.3
  3. FDA approves a new Mounjaro indication to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk.8

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Drugs@FDA: FOUNDAYO (orforglipron calcium), NDA 220934 · original approval April 1, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  2. 2
    FOUNDAYO (orforglipron) tablet, film coated · SPL version 10 · published 2026-08-13 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026

  3. 3
    ZEPBOUND (tirzepatide) injection · SPL version 40 · published 2026-09-02 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026

  4. 4
    Drugs@FDA application NDA215866 · original submission status AP · 2022-05-13 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  5. 5
    Drugs@FDA application NDA217806 · original submission status AP · 2023-11-08 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  6. 6
    Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (2025) · PMID 40960239 ↗

    The New England Journal of Medicine · Official source · Source checked November 16, 2026

  7. 7
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  8. 8
    Mounjaro (tirzepatide): NDA 215866 supplements S-044 and S-045 approval letter, August 27, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  9. 9
    Zepbound (tirzepatide): NDA 217806 supplement S-041 corrected approval letter, effective August 26, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  10. 10
    FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026